Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients with Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 “EMERGE” Study
Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2014）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要